Best Immunology Companies in Cambridge, United States
The 43 best Immunology companies in Cambridge, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Nimbus Therapeutics.
Ranked: Best Immunology companies in Cambridge
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | Nimbus Therapeutics Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 35 mo ago | 81 81 → 99 (+22%) · sector median +6% | Jeb Keiper CEO | — | — |
| 2 | Odyssey Developer of immunotherapeutics for immunological and cancer diseases 74Funding top 12%Growth top 13%Talent top 28%Moat top 31% All 7 signals ▾Fundingtop 12% Growthtop 13% Talenttop 28% Moattop 31% Techbottom 46% Marketbottom 45% Globalbottom 39% Funding: Raised $503M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Growth: Headcount 50 → 108 (+116%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 74/100 | $503M | 14 mo ago | 108 108 → 118 (+9%) · sector median +6% | Paul-Albert König Co-Founder and Sr. Director Biology | — | — |
| 3 | C4 Therapeutics Developer of small molecule drugs for treating cancer | $223M | 31 mo ago | 121 121 → 113 (-7%) · sector median +6% | Marc Cohen Co-Founder | 1,872 patents Targeted protein degradation (PROTACs) of EGFR, IKZF, and related disease proteins | 1 internship |
| 4 | Third Harmonic Bio Developer therapeutics to treat allergy and inflammatory diseases | $205M | 54 mo ago | 28 | Natalie Holles Chief Executive Officer | — | — |
| 5 | ROME Therapeutics Developer of therapeutics for cancer and autoimmune disorders | $199M | 35 mo ago | 32 | — | — | — |
| 6 | Kymeratx Developer of small molecule protein degraders for multiple disorders | $197M | 48 mo ago | 150 150 → 302 (+101%) · sector median +6% | Nello Mainolfi Co-Founder & CEO | — | 1 launch |
| 7 | Repertoire Immune Medicines Developer of T-cell based drugs for the treatment of immune disorders | $189M | 64 mo ago | 46 46 → 84 (+83%) · sector median +6% | — | 72 patents CD8‑targeted cytokine fusion proteins and lipid nanoparticle delivery for immune therapies | — |
| 8 | BeiGene Developer of targeted and immune-oncology drugs against cancer | $172M | 73 mo ago | 1,090 | John Oyler Founder & CEO | 39 patents Combination therapies targeting MAPK pathway and immune checkpoints for cancer treatment | — |
| 9 | Magenta Therapeutics Developer of stem cell-based therapies for autoimmune disease, genetics blood disorders and cancer | $150M | 63 mo ago | 75 | — | 347 patents Targeted antibody‑drug conjugates and regimens for hematopoietic stem cell transplantation | — |
| 10 | Seres Therapeutics Developer of microbiome therapeutics to treat a wide range of diseases | $134M | 26 mo ago | 332 | David Berry Founder | 274 patents Live bacterial therapeutics for gut microbiome modulation and infection/cancer treatment | — |
| 11 | CREATE Medicines Developer of messenger ribonucleic acid therapies for immune cell programming 50Funding top 20%Patents top 41%Innovation top 47%Talent bottom 49% All 5 signals ▾Fundingtop 20% Patentstop 41% Innovationtop 47% Talentbottom 49% Globalbottom 35% Funding: Raised $122M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Patents: 18 patents matched (strict assignee match) · 17 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $122M | 3 mo ago | — | Daniel Getts Co-Founder & CEO | 18 patents Design of engineered chimeric fusion protein therapeutics and gene‑delivery nucleic acid platforms. | — |
| 12 | Abata Developer of cell therapies for autoimmune and inflammatory disease | $110M | 24 mo ago | 50 | Samantha Singer President & Chief Executive Officer | — | — |
| 13 | Alltrna Developer of tRNA medicines for various therapeutic areas | $109M | 36 mo ago | 46 46 → 48 (+4%) · sector median +6% | Theonie Anastassiadis Co-Founder | — | — |
| 14 | Q32 Bio Developer of drugs for treating autoimmune disorders | $106M | 29 mo ago | 34 34 → 29 (-15%) · sector median +6% | Shelia Violette Founder & CSO | — | — |
| 15 | Mediar Therapeutics Developer of antibody-based therapeutics for treating fibrosis 19Funding top 25%Moat top 48%Talent bottom 49%News bottom 42% All 6 signals ▾Fundingtop 25% Moattop 48% Talentbottom 49% Newsbottom 42% Globalbottom 39% Marketbottom 21% Funding: Raised $105M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Moat: Editorial + unicorn rating 4/10 · 9 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 19/100 | $105M | 8 mo ago | 2 | Rahul Ballal CEO | — | — |
| 16 | Zag Bio Developer of thymus-targeted medicines for autoimmune disease treatment and prevention | $80M | 10 mo ago | — | Diane Mathis Co-Founder | — | — |
| 17 | Biogen Developer of therapies for neurodegenerative and immunology disorders | $80M | 30 mo ago | 9,482 | Heinz Co-Founder | 3,803 patents Neurology therapeutics: kinase inhibitors, antibody/drug delivery, gene therapy, and CNS medical devices. | — |
| 18 | Virdante Pharmaceuticals Antibodies to treat inflammatory and autoimmune diseases based on Sialic Switch technology. | $78M | 178 mo ago | — | Jeffrey Ravetch Founder | — | — |
| 19 | Cogent Biosciences Developer of precision therapy for genetically defined diseases | $77M | 30 mo ago | 164 164 → 294 (+79%) · sector median +6% | Charles Wilson Founder & CEO | 40 patents Small-molecule kinase inhibitors targeting PI3K, ERBB2, and JAK2 for cancer therapy | — |
| 20 | ImmusanT Develops therapeutics and diagnostics for the diagnosis and treatment of celiac disease | $72M | 95 mo ago | 2 | — | 114 patents Peptide-based immunotherapies and diagnostics for celiac disease and type‑1 diabetes | — |
| 21 | Kojin Developer of small molecule therapeutics for cancer and immune disorders | $60M | 62 mo ago | 17 | Stuart Schreiber Co-Founder | — | — |
| 22 | Rheos Medicines Developer of therapies for unmet immune-mediated diseases | $60M | 101 mo ago | 43 | Barbara Fox CEO | 9 patents MALT1 protease modulators for treating autoimmune and inflammatory diseases | — |
| 23 | Artax Biopharma Developer of small molecules for the treatment of autoimmune and inflammatory diseases | $51M | 24 mo ago | 2 | — | 67 patents Small‑molecule chromene inhibitors targeting TCR‑Nck signaling for immunotherapy. | — |
| 24 | Nereid Developer of small molecule drugs to treat cancers, neurodegenerative, and inflammatory diseases | $50M | 69 mo ago | 5 | Cliff Brangwynne Co-Founder | 2 patents Design and manufacturing of multi‑cylinder positive displacement hydraulic pumps. | — |
| 25 | Quench Bio Developer of inhibitors for innate immunity | $50M | 79 mo ago | 9 | — | — | — |
| 26 | Oncimmune Immunodiagnostics company developing biomarker platforms for cancer and immune diseases | $49M | 22 mo ago | 62 62 → 35 (-44%) · sector median +6% | Jamie Heywood Managing Director | 4 patents Immunoassay diagnostic methods and calibrators for clinical biomarker detection | — |
| 27 | Padlock Therapeutics Developing drugs targeting protein arginine deiminases (PAD) enzymes to treat autoimmune diseases. | $38M | 140 mo ago | 5 | — | — | — |
| 28 | Delinia Developing regulatory T cell based small molecule therapeutics for autoimmune diseases | $35M | 119 mo ago | 3 | — | 133 patents Engineered IL-2/peptidomimetic biologics that selectively activate regulatory T cells for autoimmune therapy | — |
| 29 | Zalicus Developing therapeutics for treatment of pain and inflammation | $30M | 182 mo ago | 2,873 | — | 34 patents Pharmaceutical formulations for ocular, immunoinflammatory and antiviral (filovirus) therapies | — |
| 30 | Cue Biopharma Precision immunotherapies to transform patients' lives by selectively modulating the immune system 67Innovation top 16%Patents top 16%News top 28%Moat top 29% All 11 signals ▾Innovationtop 16% Patentstop 16% Newstop 28% Moattop 29% Growthtop 31% Partnerstop 32% Fundingtop 36% Fin. healthtop 37% Marketbottom 49% Globalbottom 35% Techbottom 32% Innovation: 491 patents (top 5% of patent-holders) · 336 filings since 2022 vs 155 in 2017-21 Patents: 491 patents matched (strict assignee match) · 336 filings since 2022 vs 155 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $26M | 3 mo ago | 51 51 → 39 (-24%) · sector median +6% | — | 491 patents Bispecific T-cell engaging immunotherapies targeting B cells and immune regulation | — |
| 31 | Kanyos Bio Antigen-specific immune tolerance technology for two specific autoimmune indications, type-1 diabetes and… | $16M | 134 mo ago | 12 | — | — | — |
| 32 | Octagon Therapeutics Developer of small molecule based therapeutics against bacterial infections | $12M | 30 mo ago | 11 | — | — | — |
| 33 | Selventa Diagnostics Company for personalized medicine. | $12M | 177 mo ago | 30 | — | 33 patents Computational modeling and quantitative analysis of biological networks and pathways | — |
| 34 | Thymmune Developer of immunetherapeutics for immune-disorders | $7M | 16 mo ago | 9 | Stan Wang Founder & CEO | — | 1 job opening |
| 35 | Janus Biotherapeutics Virtualization and automation software optimizing computing for consumers, businesses, and cloud | $2M | 72 mo ago | 3 | Grayson Lipford Co-Founder | 43 patents Small-molecule pteridine and imidazoquinoline immune modulators for autoimmune disease therapy | — |
Top 12 Immunology companies in Cambridge
#1
Series B · Cambridge, Massachusetts · founded 2019$122Mraised▾
Developer of messenger ribonucleic acid therapies for immune cell programming. These therapies utilize lipid nanoparticle delivery systems to modify immune cells directly within the body. The technology targets specific cell types to address conditions related to oncology and autoimmunity. The approach focuses on the expression of chimeric antigen receptors to facilitate immune responses against disease targets.
- May 2026Series B$122M
#2
Public · Cambridge, Massachusetts · founded 2015 · 51 employees$26.4Mraised▾
Precision immunotherapies to transform patients' lives by selectively modulating the immune system. It is a biotechnology company engineering biologics designed to selectively engage and modulate targeted T cells. The company focuses on autoimmune diseases and cancer, aiming to restore immune balance. Their proprietary Immuno-STAT platform enhances a patient’s immune system to potentially restore health. They are developing a novel class of therapeutic biologics. The company's approach involves precision medicine, clinical development, and translational research. They are working towards establishing a new standard of care for diseases that cause human suffering and mortality. They are mobilizing the patient’s immune system to treat serious diseases.
- May 2026Post IPO$30M
- Nov 2022Post IPO$30M
- Dec 2016Series A$16.4M
- Jun 2015Seed$10M
#3
Public · Cambridge, Massachusetts · founded 2018 · 108 employees$503.2Mraised▾
Developer of immunotherapeutics for immunological and cancer diseases. It offers anti-inflammation immunotherapies such as anti-TNF antibodies and JAK inhibitors for inflammatory diseases and cancer. It has a computational drug discovery platform.
- Jun 2025Series D$214M
- Oct 2023Series C$117.2M
- Oct 2022Series B$168M
- Dec 2021Series A$218M
#4
Series B · Cambridge, Massachusetts · founded 2018 · 2 employees$105Mraised▾
Developer of antibody-based therapeutics for treating fibrosis. The company has developed therapeutics that target key fibrotic mediator proteins that aid in the development of fibrosis in chronically damaged organs.
- Dec 2025Series B$76M
- Nov 2022Series A$105M
- Mar 2021Seed—
#5
Series A · Cambridge, Massachusetts · founded 2022$80Mraised▾
Developer of thymus-targeted medicines for autoimmune disease treatment and prevention. It focuses on restoring central immune tolerance through bifunctional antibodies. These antibodies deliver self-antigens to antigen-presenting cells in the thymus. This process harnesses the body’s natural ability to train immune cells to recognize and tolerate self, thereby halting autoimmune attacks. The pipeline includes a program for Type 1 diabetes. It also includes discovery programs for other autoimmune diseases.
- Oct 2025Series A$80M
#6
Acquired · Cambridge, Massachusetts · founded 2006 · 62 employees$49.4Mraised▾
Immunodiagnostics company developing biomarker platforms for cancer and immune diseases. It leverages its proprietary ImmunoINSIGHTS platform, which uses large-scale autoantibody profiling and immune system analysis to generate actionable insights for drug development and patient stratification. Its technology enables pharmaceutical and biotechnology partners to identify disease-specific immune signatures, supporting earlier diagnosis, improved therapy development, and more precise treatment selection.
- Oct 2024Post IPO$2.9M
- Dec 2022Post IPO—
- Mar 2021Post IPO$12.3M
- Oct 2020Grant (prize money)—
#7
Series F · Cambridge, Massachusetts · founded 2009 · 81 employees$637Mraised▾
Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases. The lead candidate targets ACC for Nonalcoholic Steatohepatitis (NASH). The other drug candidate is an IRAK4 inhibitor used to target Tyk2 and KRas that mediates immune signaling.
- Sep 2023Series F$210M
- Sep 2022Series E$125M
- Jul 2021Series D$105M
- Oct 2020Series C$60M
#8
Public · Cambridge, Massachusetts · founded 2010 · 332 employees$134.1Mraised▾
Developer of microbiome therapeutics to treat a wide range of diseases. The product pipeline includes SER-109 for C. difficile infection (CDI), SER-155 for antibiotic-resistant infections and GvHD, and SER 287 for ulcerative colitis.
- 2024Post IPO—
- Nov 2017Grant (prize money)$2.5M
- Dec 2014Series D$65M
- Nov 2014Series C$48M
#9
Seed · Cambridge, Massachusetts · founded 2019 · 9 employees$7Mraised▾
Developer of immunetherapeutics for immune-disorders. It offers iPSC-derived thymic cells -based therapeutics to restore normal immune function and treat immunodeficiencies, transplant-related, and autoimmune disorders.
- Apr 2025Grant (prize money)$2.6M
- Jan 2025Grant (prize money)$2.6M
- Mar 2023Seed$7M
- Apr 2022Grant (prize money)$1.6M
#10
Deadpooled · Cambridge, Massachusetts · founded 2021 · 50 employees$110.3Mraised▾
Developer of cell therapies for autoimmune and inflammatory disease. The company is developing regulatory T cells as targeted therapies that stop immune-mediated destruction and restore homeostasis. It is used for the treatment of progressive multiple sclerosis, type-1 diabetes, and inclusion body myositis.
- Aug 2024Series A—
- Dec 2023Series A$15.3M
- Jun 2021Series A$95M
#11
Public · Cambridge, Massachusetts · founded 2016 · 121 employees$223Mraised▾
Developer of small molecule drugs for treating cancer. Its Degronimid platform incorporates highly selective small-molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural proteasome system. It has developed CFT7455 for treating hematologic malignancies, CFT8634 for sarcoma, BRAF V600E for slid tumors.
- Jan 2024Post IPO$25M
- Jun 2020Venture Debt$20M
- Jun 2020Series B$150M
- Jan 2016Series A$73M
#12
Public · Cambridge, Massachusetts · founded 2013 · 2 employees$50.9Mraised▾
Developer of small molecules for the treatment of autoimmune and inflammatory diseases. The product includes AX-158, an oral small-molecule that binds specifically to Nck and interferes with the interaction between TCR and Nck, which is responsible for T-cell activation. The company has drugs for asthma, rheumatoid arthritis, psoriasis, graft vs. host disease, multiple sclerosis, and other autoimmune and inflammatory diseases.
- Jul 2024Series C$19M
- May 2022Series C$26M
- Feb 2021Series B$2.2M
- Apr 2020Series B$2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Immunology in Cambridge is moving
A read on the academic research around Immunology in Cambridge — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 89 papers.
- University of Cambridge46
- Cambridge University Hospitals NHS Foundation Trust29
- Cambridge School15
- Cancer Research UK Cambridge Center13
- Cambridge Scientific1
- Immune system15
- Immunotherapy12
- Immune checkpoint5
- Cancer research5
- Chimeric antigen receptor4
- Immune system1→15
- Immunotherapy1→14
- Cancer1→5
- Oncology1→4
- Antigen1→3
- Immune system6
- Immunotherapy6
- Cohort2
- Cancer2
- Melanoma2
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.